Domenico Cicciarella Modica

Dr. Domenico Cicciarella Modica

ASL Roma 6, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
PTPierpaolo Trimboli
Pierpaolo Trimboli
NNNaim Nasrollah
Naim Nasrollah
Leo GuidobaldiLeo Guidobaldi
Leo Guidobaldi
STSilvia Taccogna
Silvia Taccogna
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
Anna CrescenziAnna Crescenzi
Anna Crescenzi
The reported reliability of core needle biopsy (CNB) is high in assessing thyroid nodules after inconclusive fine-needle aspiration (FNA) attempts. However, first-line use of CNB for nodules considered at risk by ultrasonography (US) has yet to be studied. The aim of this study were: 1) to evaluate the potential merit of using CNB first-line instead of conventional FNA in thyroid nodules with suspicious ultrasonographic features; 2) to compare CNB and FNA as a first-line diagnostic procedure in thyroid lesions at higher risk of cancer.

16 October 2012 in Endocrine
Verified
Journal Article
Closed access
PDF file
NNNaim Nasrollah
Naim Nasrollah
PTPierpaolo Trimboli
Pierpaolo Trimboli
Leo GuidobaldiLeo Guidobaldi
Leo Guidobaldi
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
CVClaudio Ventura
Claudio Ventura
Anna CrescenziAnna Crescenzi
Anna Crescenzi

25 February 2014 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
Anna CrescenziAnna Crescenzi
Anna Crescenzi
Leo GuidobaldiLeo Guidobaldi
Leo Guidobaldi
NNN. Nasrollah
N. Nasrollah
STS. Taccogna
S. Taccogna
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
PTP. Trimboli
P. Trimboli
BRAF(V600E) is the most frequent genetic mutation in papillary thyroid cancer (PTC) and has been reported as an independent predictor of poor prognosis of these patients. Current guidelines do not recommend the use of BRAF(V600E) mutational analysis on cytologic specimens from fine needle aspiration due to several reasons. Recently, immunohistochemistry using VE1, a mouse anti-human BRAF(V600E) antibody, has been reported as a highly reliable technique in detecting BRAF-mutated thyroid and nonthyroid cancers. The aim of this study was to test the reliability of VE1 immunohistochemistry on microhistologic samples from core needle biopsy (CNB) in identifying BRAF-mutated PTC. A series of 30 nodules (size ranging from 7 to 22 mm) from 30 patients who underwent surgery following CNB were included in the study. All these lesions had had inconclusive cytology. In all cases, both VE1 and BRAF(V600E) genotypes were evaluated. After surgery, final histology demonstrated 21 cancers and 9 benign lesions. CNB correctly diagnosed 20/20 PTC and 5/5 adenomatous nodules. One follicular thyroid cancer and 4 benign lesions were assessed at CNB as uncertain follicular neoplasm. VE1 immunohistochemistry revealed 8 mutated PTC and 22 negative cases. A 100% agreement was found when positive and negative VE1 results were compared with BRAF mutational status. These data are the first demonstration that VE1 immunohistochemistry performed on thyroid CNB samples perfectly matches with genetic analysis of BRAF status. Thus, VE1 antibody can be used on thyroid microhistologic specimens to detect BRAF(V600E)-mutated PTC before surgery.

19 December 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
FLFrancesca Lucaroni
Francesca Lucaroni
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
MMMattia Macino
Mattia Macino
Leonardo PalombiLeonardo Palombi
Leonardo Palombi
AAAlessio Abbondanzieri
Alessio Abbondanzieri
AVAntonio Vinci
Antonio Vinci
Objective To provide an overview of the currently available risk prediction models (RPMs) for cardiovascular diseases (CVDs), diabetes and hypertension, and to compare their effectiveness in proper recognition of patients at risk of developing these diseases. Design Umbrella systematic review. Data sources PubMed, Scopus, Cochrane Library. Eligibility criteria Systematic reviews or meta-analysis examining and comparing performances of RPMs for CVDs, hypertension or diabetes in healthy adult (18–65 years old) population, published in English language. Data extraction and synthesis Data were extracted according to the following parameters: number of studies included, intervention (RPMs applied/assessed), comparison, performance, validation and outcomes. A narrative synthesis was performed. Data were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Study selection 3612 studies were identified. After title/abstract screening and removal of duplicate articles, 37 studies met the eligibility criteria. After reading the full text, 13 were deemed relevant for inclusion. Three further papers from the reference lists of these articles were then added. Study appraisal The methodological quality of the included studies was assessed using the AMSTAR tool. Risk of bias in individual studies Risk of Bias evaluation was carried out using the ROBIS tool. Results Sixteen studies met the inclusion criteria: six focused on diabetes, two on hypertension and eight on CVDs. Globally, prediction models for diabetes and hypertension showed no significant difference in effectiveness. Conversely, some promising differences among prediction tools were highlighted for CVDs. The Ankle-Brachial Index, in association with the Framingham tool, and QRISK scores provided some evidence of a certain superiority compared with Framingham alone. Limitations Due to the significant heterogeneity of the studies, it was not possible to perform a meta-analysis. The electronic search was limited to studies in English and to three major international databases (MEDLINE/PubMed, Scopus and Cochrane Library), with additional works derived from the reference list of other studies; grey literature with unpublished documents was not included in the search. Furthermore, no assessment of potential adverse effects of RPMs was carried out. Conclusions Consistent evidence is available only for CVD prediction: the Framingham score, alone or in combination with the Ankle-Brachial Index, and the QRISK score can be confirmed as the gold standard. Further efforts should not be concentrated on creating new scores, but rather on performing external validation of the existing ones, in particular on high-risk groups. Benefits could be further improved by supplementing existing models with information on lifestyle, personal habits, family and employment history, social network relationships, income and education. PROSPERO registration number CRD42018088012.

19 July 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
MMMassimo Maurici
Massimo Maurici
Gian Loreto D'AlòGian Loreto D'Alò
Gian Loreto D'Alò
CMCinzia Mozzetti
Cinzia Mozzetti
AMAlessandra Messina
Alessandra Messina
PFPATRIZIA DE FILIPPIS
PATRIZIA DE FILIPPIS
Mobile phones (MPs) are commonly used both in the personal and professional life. We assessed microbiological contamination of MPs from 108 students in healthcare professions (HPs), in relation to their demographic characteristics and MPs handling habits, collected by means of a questionnaire. Cultural and biochemical tests were performed, and statistical analyses were carried out. Staphylococci were present in 85% of MPs, Enterococci in 37%, Coliforms in 6.5%; E. coli was never detected. Staphylococcus epidermidis was the most frequently isolated staphylococcal species (72% of MPs), followed by S. capitis (14%), S. saprophyticus, S. warneri, S. xylosus (6%), and by S. aureus (4%). Heterotrophic Plate Counts (HPC) at 37 °C, ranged from 0 to 1.2 × 104 CFU/dm2 (mean = 362 CFU/dm2). In univariate analysis, the male gender only was significantly associated with higher HPCs and enterococcal contamination. Multiple linear regression models explained only 17% and 16% of the HPC 37 °C and staphylococcal load variability, respectively. Developing specific guidelines for a hygienic use of MPs in clinical settings, for preventing cross-infection risks, is advisable, as well as introducing specific training programs to HP students. MPs decontamination procedures could also be implemented in the community.

7 May 2015 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
Anna CrescenziAnna Crescenzi
Anna Crescenzi
PTP. Trimboli
P. Trimboli
DMDomenico Cicciarella Modica
Domenico Cicciarella Modica
CTC. Taffon
C. Taffon
Leo GuidobaldiLeo Guidobaldi
Leo Guidobaldi
GZG. Zelano
G. Zelano
In the last decade, several molecular markers have been proposed to improve the diagnosis of thyroid nodules. Among these, mutations in the telomerase reverse transcriptase (TERT) promoter have been correlated to malignant tumors, characterized by highest recurrence and decreased patients’ survival. This suggests an important role of TERT mutational analysis in the clinical diagnosis and management of thyroid cancer patients. The aim of the study was to demonstrate the adequacy of core needle biopsy (CNB) for the preoperative assessment of TERT mutational status, to reach a more accurate definition of malignancy and a more appropriate surgical planning. Indeed, CNB is gaining momentum for improving diagnosis of thyroid nodules deemed inconclusive by fine needle aspirate (FNA). The study included 50 patients submitted to CNB due to inconclusive FNA report. TERT mutational status was correlated with BRAF mutation, definitive histology, and post-operative TNM staging of the neoplasia. C228T mutation of the TERT promoter was reported in 10% of the papillary carcinomas (PTC) series. When compared with final histology, all cases harboring TERT mutation resulted as locally invasive PTCs. The prevalence of TERT mutated cases was 17.6% among locally advanced PTCs. TERT analysis on CNB allows the assessment of the pathological population on paraffin sections before DNA isolation, minimizing the risk of false negatives due to poor sampling that affects FNA, and gathering aggregate information about morphology and TERT mutational status. Data indicating a worse outcome of the tumor might be used to individualize treatment decision, surgical option, and follow-up design.